Thiotepa
| Evidence Level: L5 | Predicted Indications: 75 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Thiotepa |
| DrugBank ID | DB04572 |
| Brand Names (EU) | Tepadina, Thiotepa Riemser |
| Evidence Level | L5 |
| Predicted Indications | 75 |
| Top Prediction Score | 99.53% |
Approved Indication (EMA)
Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products: with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients. Thiotepa Riemser is indicated, in combination with other
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary non-gestational choriocarcinoma of ovary | 99.53% | DL |
| 2 | ovarian clear cell adenocarcinoma | 99.21% | DL |
| 3 | female breast carcinoma | 98.97% | DL |
| 4 | yolk sac tumor | 98.88% | DL |
| 5 | adult germ cell tumor | 98.51% | DL |
| 6 | ovarian mucinous adenocarcinoma | 98.51% | DL |
| 7 | hereditary breast ovarian cancer syndrome | 98.47% | DL |
| 8 | maligant granulosa cell tumor of ovary | 98.41% | DL |
| 9 | testicular yolk sac tumor, papillary pattern | 98.36% | DL |
| 10 | enteric pattern testicular yolk sac tumor | 98.36% | DL |
| 11 | reticular pattern testicular yolk sac tumor | 98.36% | DL |
| 12 | testicular yolk sac tumor, hepatoid pattern | 98.36% | DL |
| 13 | polyvesicular vitelline pattern testicular yolk sac tumor | 98.36% | DL |
| 14 | testicular yolk sac tumor, macrocystic pattern | 98.36% | DL |
| 15 | testicular yolk sac tumor, endodermal sinus pattern | 98.36% | DL |
| 16 | testicular yolk sac tumor, solid pattern | 98.36% | DL |
| 17 | childhood ovarian yolk sac tumor | 98.30% | DL |
| 18 | ovarian yolk sac tumor, hepatoid pattern | 98.29% | DL |
| 19 | ovarian yolk sac tumor, polyvesicular vitelline pattern | 98.29% | DL |
| 20 | ovarian yolk sac tumor, glandular pattern | 98.29% | DL |
Showing top 20 of 75 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.